Chengdu Olymvax Biopharmaceuticals Inc. (SHSE: 688319)
Health Care · Biotechnology · CN
CN¥30.09
-3.50% today · +16.8% 1Y
Chengdu Olymvax Biopharmaceuticals Inc. (SHSE: 688319) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.82B and employs 436 people.
Over the last twelve months the share price has gained 16.8%, trading between 20.41 and 44.90.
Tweenvest scores Chengdu Olymvax Biopharmaceuticals Inc. across four factors: quality 60/100, value 34/100, growth 74/100. Its strongest factor is growth.
688319 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.82B
- Revenue (TTM)
- $111.83M
- P/E
- —
- EPS
- -0.06
- Dividend yield
- —
- Beta (5Y)
- 0.58
- 52-week high
- CN¥44.90
- 52-week low
- CN¥20.41
- Avg volume (3M)
- —
- Shares outstanding
- 405.41M
- Employees
- 436
- Next earnings
- —
About Chengdu Olymvax Biopharmaceuticals Inc.
Chengdu Olymvax Biopharmaceuticals Inc. specializes in the research, development, and distribution of vaccines. Their current product portfolio includes immunizations against tetanus, a severe and often fatal infectious disease that damages the nervous system due to toxins produced by Clostridium tetani, alongside a vaccine for Haemophilus influenzae type b. Beyond their existing offerings, the company is actively advancing new vaccine candidates targeting Staphylococcus aureus, a prevalent bacterium responsible for both hospital-acquired and community infections, and illnesses associated with Group A streptococcus. This enterprise was established in 2009 and operates from its base in Chengdu, China.
- ISIN
- CNE1000051H8
- Founded
- 2009
- Listed since
- Jun 8, 2021
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Intellia Therapeutics, Inc.NasdaqGM: NTLA | $1.83B | $12.69 | -2.91% |
| Xencor, Inc.NasdaqGM: XNCR | $1.83B | $24.78 | +0.61% |
| Zymeworks Inc.NasdaqGS: ZYME | $1.83B | $25.41 | -1.47% |
| Biohaven Ltd.NYSE: BHVN | $1.82B | $11.78 | -2.48% |
| Mesoblast LimitedASX: MSB | $1.81B | AU$2.00 | -1.96% |
| UroGen Pharma Ltd.NasdaqGM: URGN | $1.80B | $37.51 | +1.83% |
| Zenas BioPharma, Inc.NasdaqGS: ZBIO | $1.78B | $26.82 | -1.61% |
| Hualan Biological Vaccine Inc.SZSE: 301207 | $1.77B | CN¥19.88 | +1.90% |
Figures last refreshed Oct 11, 2026.